| Revenue growth | 15.8% YoY for Q4; 27.5% YoY for full year FY26. |
|---|---|
| Margins | EBITDA margin at 20.2%; PAT margin at 7.6%. |
| Demand visibility | Strong for respiratory and dermatology across US, EU, and India. |
| Management confidence | High: cites 'defining year' and validated innovation capabilities. |
Growth
Revenue: ₹37,706m (+15.8% YoY). EU (+21.4%) and US (+29.4%) led growth; India business grew 8.2%.
Outlook
Focus on global RYALTRIS expansion, UK respiratory portfolio in FY27, and oncology launches in Emerging Markets.
Risks
Macro-economic parameters, currency/interest rate fluctuations, and increasing pharmaceutical competition globally.
Earnings Call filed with BSE, NSE: GLENMARK. Summary written with AI assistance from the document.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,380.00
- Market cap
- ₹67,169 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 37.4×Sector 50.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Glenmark reported Q1 FY27 consolidated revenue of INR 40,185 million, a 23.1% YoY increase. Performance was driven by India growth (15.5%) and North America recovery (41.1%).
- Call
- Guides 15% growth
Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways
Glenmark delivered robust 23.1% revenue growth for Q1 FY27, driven by strong recovery in North America and steady India outperformance, despite persistent geopolitical cost pressures.
- Call
- Guides 15% growth